Brick & Kyle Associates’s Novo Nordisk NVO Stock Holding History

Brick & Kyle Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-700	Closed	-$15K	–	435
2016 Q3	$15K	Hold	700	–	–	0.01%	310
2016 Q2	$19K	Hold	700	–	–	0.02%	276
2016 Q1	$19K	Hold	700	–	–	0.02%	265
2015 Q4	$20K	Hold	700	–	–	0.02%	252
2015 Q3	$19K	Buy	+700	New	+$19.8K	0.02%	264

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

Brick & Kyle Associates's NVO Position: Q4 2016 in Review

Brick & Kyle Associates sold out of Novo Nordisk (NVO) in Q4 2016, closing a stake of 700 shares — an estimated $15K sold.

Brick & Kyle Associates first reported a position in NVO in Q3 2015 and held it in 5 quarters. The position peaked at $20K in Q4 2015. 483 funds tracked by Wall St. Rank hold NVO as of Q4 2016.

Brick & Kyle Associates reported no remaining Novo Nordisk position as of Q4 2016 after selling out during the quarter.
Brick & Kyle Associates sold 700 Novo Nordisk shares in Q4 2016, an estimated $15K.
Brick & Kyle Associates first reported a position in Novo Nordisk in Q3 2015 and held it in 5 quarters.
Brick & Kyle Associates's Novo Nordisk position peaked at $20K in Q4 2015.
483 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2016.

Based on Brick & Kyle Associates's 13F filing for Q4 2016, filed 5 Jan 2017.